Covalent agonists for studying G protein-coupled receptor activation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 29, 2014, Pages 10744-10748

  Weichert, Dietmar ^a   Kruse, Andrew C ^b   Manglik, Aashish ^b   Hiller, Christine ^a   Zhang, Cheng ^b   Hub̈ner, Harald ^a   Kobilka, Brian K ^b   Gmeiner, Peter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemical biology; Chemical probes; Structural biology

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; DOPAMINE; G PROTEIN COUPLED RECEPTOR; HISTAMINE; LIGAND; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN;

AGONIST; ARTICLE; COVALENT AGONIST; COVALENT BOND; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; NUCLEOPHILICITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS;

CHEMICAL BIOLOGY; CHEMICAL PROBES; STRUCTURAL BIOLOGY;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; HUMANS; LIGANDS; MODELS, MOLECULAR; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84904704143     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1410415111     Document Type: Article

References (36)

1. Nygaard R, et al. (2013) The dynamic process of β(2)-adrenergic receptor activation. Cell 152(3):532-542.
2. Kobilka B, Schertler GF (2008) New G-protein-coupled receptor crystal structures: Insights and limitations. Trends Pharmacol Sci 29(2):79-83.
3. Granier S, Kobilka B (2012) A new era of GPCR structural and chemical biology. Nat Chem Biol 8(8):670-673.
4. Maeda S, Schertler GF (2013) Production of GPCR and GPCR complexes for structure determination. Curr Opin Struct Biol 23(3):381-392.
5. Rasmussen SG, et al. (2011) Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature 469(7329):175-180.
6. Kruse AC, et al. (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504(7478):101-106.
7. Newman AH (1991) Irreversible ligands as probes for drug receptors. NIDA Res Monogr 112:256-283.
8. Baker SP, Deyrup MD (1994) Development of novel irreversible ligands. Neuroprotocols 4(1):66-75.
9. 4 receptor. Br J Pharmacol 170(1):89-100.
10. Tsotinis A, Afroudakis PA, Davidson K, Prashar A, Sugden D (2007) Design, synthesis, and melatoninergic activity of new azido- and isothiocyanato- substituted indoles. J Med Chem 50(25):6436-6440. (Pubitemid 350250431)
11. Picone RP, Fournier DJ, Makriyannis A (2002) Ligand based structural studies of the CB1 cannabinoid receptor. J Pept Res 60(6):348-356. (Pubitemid 36071898)
12. Milecki J, et al. (1987) Carbostyril derivatives having potent β-adrenergic agonist properties. J Med Chem 30(9):1563-1566. (Pubitemid 17135900)
13. Xiang Z, et al. (2013) Adding an unnatural covalent bond to proteins through proximity-enhanced bioreactivity. Nat Methods 10(9):885-888.
14. Yan F, et al. (2009) Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor. Biochemistry 48(29):6898-6908.
15. Kung M-P, Mu M, Zhuang Z-P, Kung HF (1996) NCS-MPP (4-(2′-methoxy- phenyl)-1-[2′-(N-2″-pyridyl)-p-isothiocyanobenz amido]-ethyl- piperazine): A high affinity and irreversible 5-HT1A receptor ligand. Life Sci 58(3):177-186.
16. Baker SP, Liptak A, Pitha J (1985) Irreversible inactivation of the β-adrenoreceptor by a partial agonist. Evidence for selective loss of the agonist high affinity binding sites. J Biol Chem 260(29):15820-15828. (Pubitemid 16169358)
17. Buck E, Bourne H, Wells JA (2005) Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor. J Biol Chem 280(6):4009-4012. (Pubitemid 40288561)
18. Buck E, Wells JA (2005) Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor. Proc Natl Acad Sci USA 102(8):2719-2724. (Pubitemid 40299859)
19. Hardy JA (2008) A link means a lot: Disulfide tethering in structure-based drug design. Comput Struct Approaches Drug Discovery, eds Stroud J, Finer-Moore J (RSC Publishing, Cambridge, UK), pp 319-348.
20. Rosenbaum DM, et al. (2011) Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature 469(7329):236-240.
21. D'Ischia M, Palumbo A, Prota G (1988) Adrenalin oxidation revisited. New products beyond the adrenochrome stage. Tetrahedron 44(20):6441-6446.
22. Whorton MR, et al. (2007) A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci USA 104(18):7682-7687. (Pubitemid 47185966)
23. Chee MJS, et al. (2008) The third intracellular loop stabilizes the inactive state of the neuropeptide Y1 receptor. J Biol Chem 283(48):33337-33346.
24. Ring AM, et al. (2013) Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Nature 502(7472):575-579.
25. Caffrey M, Cherezov V (2009) Crystallizing membrane proteins using lipidic mesophases. Nat Protoc 4(5):706-731.
26. Westfield GH, et al. (2011) Structural flexibility of the G α s α-helical domain in the β2-adrenoceptor Gs complex. Proc Natl Acad Sci USA 108(38):16086-16091.
27. Rasmussen SG, et al. (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477(7366):549-555.
28. Steyaert J, Kobilka BK (2011) Nanobody stabilization of G protein-coupled receptor conformational states. Curr Opin Struct Biol 21(4):567-572.
29. Kobilka BK (1995) Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. Anal Biochem 231(1):269-271.
30. Zou Y, Weis WI, Kobilka BK (2012) N-terminal T4 lysozyme fusion facilitates crystallization of a G protein coupled receptor. PLoS ONE 7(10):e46039.
31. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276(Macromolecular Crystallography, Part A):307-326.
32. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40(Pt 4):658-674. (Pubitemid 47080256)
33. Afonine PV, et al. (2012) Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr D Biol Crystallogr 68(Pt 4):352-367.
34. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132.
35. Hübner H, Haubmann C, Utz W, Gmeiner P (2000) Conjugated enynes as nonaromatic catechol bioisosteres: Synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D(3) subtype. J Med Chem 43(4):756-762. (Pubitemid 30127169)
36. Broach JR, Thorner J (1996) High-throughput screening for drug discovery. Nature 384(6604, Suppl):14-16. (Pubitemid 26374533)